HIGH DOSE CYCLOPHOSPHAMIDE AND RITUXIMAB IN MULTIPLE MYELOMA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study proposed the administration of two doses of rituximab 375 mg/m2 prior to cyclophosphamide 50 mg/kg/d for four days. Rituximab is being administered prior to cyclophosphamide to achieve maximal lymphoid reduction. It will then be followed by cyclophosphamide 50 mg/kg/d for four days in an effort to achieve maximal cytoreduction of the mature plasma cells. Once hematopoietic recovery occurs, rituximab will be given weekly times four at the time when the myeloma burden should be lowest, immediately following high dose therapy and then every three months for 3 doses to further eliminate residual myeloma stem cells which may be present. Patients are eligible for this study if they have primary refractory or relapsed Multiple Myeloma after prior therapy, and have Durie-Salmon Stage II or III disease at any time since diagnosis. Additional eligibility criteria include sensitivity to salvage therapy, age >18 years, FEV > 50%, FVC > 50%, normal left ventricular cardiac ejection fraction, and chromosome 13 deletion.